Nouvelle Clinique Des Dentellieres — Clinical Trial Site

8 Registered trials

4 Currently recruiting

Organisation

Nouvelle Clinique Des Dentellieres

Location

Valenciennes, France

Identifier

ORG-100043946

Address

8 Avenue Vauban, 59300, France

Departments

033017: Oncology
Centre Les Dentellières
Oncologie
Oncology
Radiothérapie
Radiotherapy

Clinical trials at this site (8)

Search interface

Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Ended

2023-508264-29-00 Advanced Renal Cell Carcinoma with Intermediate- or Poo 5 2019-06-11
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Localised unresectable adenocarcinoma or squamous cell 4 2019-05-13
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 oligometastatic hormone sensitive prostate cancer 4 2019-03-21